Stock Market Update - July 7, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. CRNX - Crinetics Pharmaceuticals, Inc.
Price: $83.53 | Change: +98.74% ($41.5)
CRNX absolutely exploded with a near 98.74% gain! This dramatic surge for Crinetics Pharmaceuticals, Inc. came swiftly around July 8, 2026, driven by the exciting news that the company is being acquired by Vertex Pharmaceuticals.
Vertex agreed to an all-cash deal, valuing Crinetics at approximately $10 billion, or $85.00 per share. This offer was a significant premium, more than doubling Crinetics' closing price from just a couple of days prior. The acquisition, expected to close in Q3 2026, positions Crinetics for a clear exit.
For Vertex, this deal is all about expanding its footprint in rare endocrine diseases. They are gaining Crinetics' promising portfolio, including the recently FDA-approved PALSONIFY for acromegaly and a key drug candidate for congenital adrenal hyperplasia in late-stage trials. Vertex projects these new assets could generate over $5 billion in peak annual revenues, a strong strategic move that immediately re-priced CRNX shares close to the $85 offer.
2. CLRO - ClearOne, Inc.
Price: $13.84 | Change: +97.71% ($6.84)
CLRO saw an astonishing 97.71% gain, making headlines. This dramatic surge was primarily driven by the announcement of a definitive merger agreement with Cortigent, Inc., a cutting-edge neurostimulation technology company. This deal marks a significant strategic pivot for ClearOne, transforming it from a communications firm into a medical technology entity focused on brain-computer interfaces (BCI) and neurostimulation. Upon closing, the combined company will be renamed Cortigent Holdings, Inc., and is expected to trade under the new Nasdaq ticker symbol "CRGT".
Cortigent, a subsidiary of Vivani Medical (VANI), is known for innovations like its Orion artificial vision system, which has received FDA Breakthrough Device Designation. While existing ClearOne shareholders are anticipated to experience significant dilution, this bold move into the high-potential medical technology sector was the clear catalyst for the stock's impressive climb.
3. TVRD - Tvardi Therapeutics, Inc.
Price: $3.1 | Change: +54.23% ($1.09)
TVRD rocketed up 54.23% around July 8, 2026, after Tvardi Therapeutics, a clinical-stage biopharmaceutical company, announced positive Phase 1 clinical trial results for its next-generation drug, TTI-109. This drug is designed to target STAT3, a protein involved in various diseases.
Investors reacted strongly to the news that TTI-109 demonstrated improved tolerability compared to its predecessor, significantly reducing side effects like the duration of diarrhea. The study also confirmed the drug effectively converts to its active form and successfully hits its target, showing reductions in specific immune cells that drive disease.
What makes this particularly interesting is that these compelling results support Tvardi's plans to advance TTI-109 into crucial Phase 2 studies. The drug aims to address STAT3-driven dermatologic (skin) and gastrointestinal (digestive system) diseases, potentially offering new treatment options in these areas.
4. SKIN - The Beauty Health Company
Price: $1.11 | Change: +47.04% ($0.3551)
SKIN saw an impressive surge, rocketing up by 47.04%! This significant leap for The Beauty Health Company (now SkinHealth Systems Inc.) was sparked by a major announcement on July 7, 2026: a new U.S. FDA clearance. Their SkinStylus microneedling device received approval for improving the appearance of wrinkles around the eyes in adults.
This isn't just another regulatory win; it expands the SkinStylus's clinically supported uses, making it unique. It's now the only microneedling device with FDA-cleared indications for facial acne scars, periorbital (around the eye) wrinkles, and abdominal hypertrophic scars. This positions SkinHealth Systems Inc. strongly in the rapidly growing microneedling market, which saw U.S. consumer spending jump 33% last year.
5. AKTX - Akari Therapeutics, Plc
Price: $15.48 | Change: +42.02% ($4.58)
AKTX shot up an impressive 42.02% recently as Akari Therapeutics, Plc announced a series of positive developments around July 2026. A major driver was the successful completion of a substantial capital raise, securing roughly $8.3 million through a private placement and warrant exercises. This financial boost significantly strengthens the company's balance sheet, providing crucial funds to advance its drug pipeline.
Further fueling investor optimism are encouraging preclinical results for Akari's lead targeted cancer drug candidate, AKTX-101. Data presented at a major oncology meeting showcased this treatment's promising activity in difficult-to-treat pancreatic cancer models. Adding to the buzz, the company appointed a highly respected oncology leader to its Scientific Advisory Board and secured a key European patent for its drug delivery technology. This combination of financial strength, scientific progress, and strategic team additions is what has caught investors' attention.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.